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Purpose: Obstructive jaundice in patients with hepatocellular carcinoma (HCC) is 
uncommon (0.5--13%). Unlike other causes of obstructive jaundice, the role of en-
doscopic intervention in obstructive jaundice complicated by HCC has not been 
clearly defined. The aim of this study was to evaluate the clinical characteristics of 
obstructive jaundice caused by HCC and predictive factors for successful endo-
scopic intervention. Materials and Methods: From 1999 to 2009, 54 patients with 
HCC who underwent endoscopic intervention to relieve obstructive jaundice were 
included. We defined endoscopic intervention as a clinical success when the ob-
structive jaundice was relieved within 4 weeks. Results: Clinical success was 
achieved in 23 patients (42.6%). Patients in the clinical success group showed bet-
ter Child-Pugh liver function (C-P grade A or B/C; 17/6 vs. 8/20), lower total bili-
rubin levels (8.1±5.3 mg/dL vs. 23.1±10.4 mg/dL) prior to the treatment, and no 
history of alcohol consumption. The only factor predictive of clinical success by 
multivariate analysis was low total bilirubin level at the time of endoscopic inter-
vention, regardless of history of alcohol consumption [odds ratio 1.223 (95% con-
fidence interval, 1.071--1.396), p=0.003]. The cut-off value of pre-endoscopic 
treatment total bilirubin level was 12.8 mg/dL for predicting the clinical prognosis. 
Median survival after endoscopic intervention in the clinical success group was nota-
bly longer than that in the clinical failure group (5.6 months vs. 1.5 months, 
p≤0.001). Conclusion: Before endoscopic intervention, liver function, especially to-
tal bilirubin level, should be checked to achieve the best clinical outcome. Endoscop-
ic intervention can be helpful to relieve jaundice in well selected patients with HCC.
Key Words:   Hepatocellular carcinoma, obstructive jaundice, endoscopic retro-
grade cholangiopancreatography, palliative treatment
INTRODUCTION
Jaundice is a common presentation of hepatocellular carcinoma (HCC) and occurs 
in 5--44% of patients. However, obstructive jaundice is quite uncommon in HCC 
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were divided into three groups: type 1 obstruction due to an 
intraluminal obstruction of the bile duct caused by a tumor 
thrombus or floating tumor fragments; type 2 caused by he-
mobilia; and type 3 due to extraluminal tumor or nodal 
compression.1,4 Locations of biliary obstruction were classi-
fied according to the extent of tumor thrombi or obstruc-
tion. Location of obstruction was mainly diagnosed by 
ERCP. The locations of obstruction were divided into six 
groups: the type I location of obstruction was an obstruc-
tion of a unilateral intrahepatic duct (IHD) with a biliary tu-
mor thrombi or tumor compression, without contralateral 
IHD involvement. The type II location of obstruction in-
volved a unilateral IHD with hilar area involvement. Type 
III obstruction was defined by obstruction of a bilateral IHD 
with hilar involvement. Type IV obstruction involved only 
extrahepatic ducts (EHD). Type V location of biliary ob-
struction comprised multifocal involvement of both the IHD 
and EHD, and Type VI obstruction was defined as solitary 
hilar or common hepatic duct (CHD) involvement.
Endoscopic intervention was performed by insertion of a 
biliary plastic stent or metal stent, endoscopic nasobiliary 
drainage (ENBD), or sphincterotomy (EST) alone. The 
method of intervention was decided upon by the endosco-
pists at the time of intervention. We primarily tried to insert 
a biliary stent for treatment of HCC patients with obstruc-
tive jaundice. However, stent insertion was not available in 
some cases with severe bile duct stenosis, etc. In such cas-
es, other endoscopic interventions, such as ENBD or EST, 
were selected. 
Biliary stent insertion was performed with plastic or metal 
stents. Plastic stents showed relatively shorter patency than 
that of metal stents. Therefore, inoperable cancer patients 
with obstructive jaundice preferred to have metal stents in-
serted than plastic stents. In this study, although this result did 
not show statistical significance, metal stents were inserted in 
cases with intraluminal tumor infiltration. On the other hand, 
plastic stents tended to be used in patients with obstructive 
jaundice caused by hemobilia or extraluminal compression. 
The patients were divided into two groups based on the 
success or failure to relieve obstructive jaundice. Clinical 
success was defined as a bilirubin level that decreased to nor-
mal bilirubin status or more than half the bilirubin level com-
pared to that in the time of ERCP within 4 weeks after endo-
scopic intervention. 
Statistical analysis
Continuous data were expressed as mean±SD or medians, 
with an incidence of 0.5--13%.1 The synonyms for obstruc-
tive jaundice in HCC are icteric type hepatoma or choles-
tatic type HCC.2 Obstructive jaundice in HCC can be 
caused by tumor thrombus in the bile duct, hemobilia, and 
extrinsic tumor compression of the extrahepatic biliary tree. 
In Korea, the death rate of HCC has been reported at 
21.8/100000 in 2011 by the National Cancer Information 
Center; HCC has the second highest cancer mortality next to 
lung cancer. The prognosis for patients with hepatocellular 
jaundice in HCC is dismal. On the other hand, the prognosis 
for patients with obstructive jaundice caused by extra-hepat-
ic duct obstruction is better.2,3 The mean survival of patients 
with obstructive jaundice caused by HCC treated with sim-
ple biliary drainages varies from 2.5 to 4.5 months, and 
when treated with combined palliative therapies, it ranges 
from 8 to 13.4 months.1 Therefore, in cases of obstructive 
jaundice complicated by HCC, active endoscopic interven-
tion, including endoscopic retrograde cholangiopancreatog-
raphy (ERCP), could improve the prognosis. 
However, the role of endoscopic intervention in HCC is 
not yet clearly defined. It is important to predict the out-
comes of invasive interventions in patients with HCC, who 
have a bleeding tendency and other various conditions that 
can increase the rate of treatment-related complications. The 
aim of this study was to analyze the clinical characteristics 
of patients with obstructive jaundice caused by HCC who 
underwent endoscopic intervention and to identify predic-
tors of successful outcomes. 
MATERIALS AND METHODS
　　　
We included 54 patients with HCC who were treated from 
1999 to 2009 with ERCP for obstructive jaundice at Sever-
ance Hospital, Yonsei University College of Medicine, in 
Seoul, Korea. The median age of the patients was 56.3 years 
(range: 38 to 78 years). Forty-seven patients (87%) were 
male. The diagnosis of HCC was based on either typical 
imaging findings on abdominal CT, liver MRI, or hepatic 
angiography, combined with elevated tumor markers such 
as α-fetoprotein (AFP); vitamin K absence or antagonist II 
(PIVKA-II); or pathologic confirmation. 
Obstructive jaundice was diagnosed by the typical sign 
of biliary tree obstruction (narrowing and dilatation at distal 
and proximal parts of the biliary tract) on imaging studies 
and biochemical abnormalities, such as elevated total and di-
rect bilirubin. Mechanisms of obstructive jaundice in HCC 
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or ampullary adenoma.
Even less, ENBD insertion could not be possible in spe-
cific cases with bile duct stenosis by post-transcatheter arte-
rial chemoembolization (TACE) glue damage or atrophy. 
Finally, EST was done in those cases.
Among the methods for relieving jaundice, the insertion 
of biliary stents, both metal and plastic, were most common 
(n=33, 61.1%). There were no severe procedure-related 
complications, such as perforation or death. Stent dysfunc-
tion developed in 8 patients during the follow-up period. 
Stent obstruction was observed in 4 patients caused by tu-
and categorical data were expressed as the number of pa-
tients with a specified condition or clinical variable. The de-
tection of significant differences was performed using Stu-
dent’s t-test for continuous variables and the chi-square test 
for categorical variables. Logistic regression was carried 
out via multivariate analysis. These tests were also used to 
determine whether each variable considered was a signifi-
cant predictor of clinical outcomes (success or failure). For 
predicting clinical outcomes, a cut-off value for pre-endo-
scopic treatment total bilirubin level was determined using 
receiver operating characteristic (ROC) curves and area un-
der the ROC curve analysis. Median overall survival was 
estimated using Kaplan-Meier analysis. All analyses were 
performed using SPSS software (ver. 12.0, Chicago, IL, 
USA). All p-values <0.05 were considered significant.
 
RESULTS
 
The clinical characteristics of the patients are summarized 
in Table 1. Viral hepatitis B or C was the predominant un-
derlying cause of liver disease (n=48, 88.9%), and most of 
the patients had cirrhosis (n=47, 87%). Hepatic function 
was evaluated with Child-Pugh classification and the num-
bers of patients with Child-Pugh class A, B, and C were 7 
(13%), 21 (39%), and 26 (48%), respectively. At the time of 
ERCP, the mean total bilirubin was 15.5 mg/dL, mean se-
rum alkaline phosphatase was 280.2 IU/L, and mean gam-
ma-glutamyl transferase was 272.4 IU/L (Table 1). 
The mechanisms of obstructive jaundice, locations of bil-
iary obstruction, and modalities of endoscopic interventions 
are summarized in Table 2 and 3. The mechanisms of ob-
structive jaundices in HCC were as follows: intraluminal 
tumor thrombosis (n=17), cancer infiltration (n=35), hemo-
bilia (n=6), compression by tumor mass (n=7) or lymph 
node (n=3), or a combination of the above. Among them, 
type 1 obstructive jaundice (intraluminal tumor obstruction) 
was most common. Each type of obstructive jaundice may 
have been combined with other types in some cases. For 
the location of obstructions, the most common level of bili-
ary obstruction involved hilar lesions or common hepatic 
ducts (type VI). Endoscopic interventions included ENBD 
(n=6), plastic stent (n=17), metal stent (n=16), and EST 
(n=12). Stent insertion was preferentially considered in en-
doscopic intervention. However, stent could not be inserted 
in some cases. We tried to perform ENBD for cases that 
showed bile duct stricture caused by cancer, huge abscess, 
Table 1. Patient Characteristics 
Patient characteristics  n (%)
Mean age, yrs 56.3±9.6 (range: 38--78)
Sex, M/F (%)   47/7 (87/13)
Chief complaint, n (%)
    Icterus    4 (8.3)
    Abdominal pain    13 (27.1)
    Asymptomatic mass detection    26 (54.2)
    General fatigue      5 (10.4)
Causes of hepatitis, n (%)
    HBV+/HCV+/alcoholic/NBNC 42/6/2/4 (77.8/11.1/3.7/7.4)
Liver cirrhosis (%) 47 (87)
Child-Pugh classification, n (%)
    A or B/C 28/26 (52/48)
Portal vein thrombosis, n (%)    29 (53.7)
Clinical history
    Alcohol use, n (%)    30 (57.7)
    Smoking, n (%)    24 (46.2)
    Amount of smoking (PYS),    
      mean±SD
11.7±17.1 (PYS)
Laboratory tests at diagnosis (mean±SD)
    Platelet (103/μL) 152.0±78.1
    Prothrombin time (%)   72.9±19.8
    Albumin (g/dL)   3.00±0.47
    AST (IU/L) 126.1±93.6
    ALT (IU/L)   76.5±55.1
    Total bilirubin (mg/dL)   15.5±11.5
    Direct bilirubin (mg/dL) 13.2±7.9
    Alkaline phosphatase (IU/L)    280.2±170.8
    rGT (IU/L)   272.4±181.5
    Tumor marker elevation; n(%) median (range)   
    αFP (>7 IU/mL)
43/54 (79.6)/1140.9
(8.1--58585.0)
    PIVKA-II (>40 IU/mL)
31/34 (88.5%)/1887.1 
(78.0--2000.0)
NBNC, NonBNonC, non-viral hepatitis; PYS, pack years, calculated by 
multiplying the number of packs of cigarettes smoked per day by the num-
ber of years the person has smoked; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; rGT, gamma-glutamyl transferase; αFP, 
α-fetoprotein; PIVKA-II, vitamin K absence or antagonist II.
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mor growth and thrombi. These 4 patients were treated by 
stent changes in 2 cases, stent-in-stent insertion in 1 case, 
and stent dilatation by ballooning in 1 case. Stent migration 
occurred in 1 patient. The causes of stent dysfunction in the 
other 3 patients were biloma leakage, bleeding at previous 
endoscopic sphincteroscopy site, and infection due to huge 
abscess. 
HCC is a hypervascular tumor; therefore, stent obstruc-
tion can easily be caused by intraluminal tumor thrombus 
or infiltration (type 1 obstructive jaundice). Three of 4 pa-
tients with stent obstruction showed type 1 obstructive jaun-
dice due to intraluminal thrombus or tumor infiltration. The 
other one patient had type 3 jaundice (i.e., extraluminal 
lymph node compression). One patient with stent migration 
also showed type 1 jaundice. 
There were no significant differences in age, sex, causes 
of hepatitis, the presence of cirrhosis, and treatment modali-
ties of HCC between clinical success and failure groups. 
HCC patients that achieved clinical success were treated 
with TACE, chemotherapy, radiotherapy, or radiofrequency 
ablation. 
The two groups did not differ in the mechanisms of ob-
structive jaundice, locations of biliary obstruction, and mo-
dalities of endoscopic interventions. However, mean total bil-
irubin was significantly higher (23.1±10.4 mg/dL vs. 8.1±5.3 
mg/dL, p≤0.001) and albumin was significantly lower (2.8± 
0.4 g/dL vs. 3.1±0.4 g/dL, p=0.013) in clinical failure group 
than in the clinical success group. Furthermore, the cut-off 
value of pre-treatment total bilirubin level for predicting the 
clinical prognosis after endoscopic intervention was 12.8 
Table 2. Classification of Obstructive Jaundice in HCC 
Number of 
patients (%)
Mechanisms of obstructive jaundice*
    Intraluminal tumor thrombosis/infiltration  17/35
    Hemobilia    6
    Extraluminal compression by tumor/node    7/3
Locations of obstruction
    Type I (IHD involvement without 
      contralateral IHD involvement)
  8 (14.8)
    Type II (IHD involvement with hilar 
      involvement)
12 (22.2)
    Type III (bilateral IHD involvement with 
      hilar involvement)
3 (5.6)
    Type IV (solitary EHD involvement)   6 (11.1)
    Type V (multifocal involvement in both 
      IHD and EHD)
  8 (14.8)
    Type VI (solitary hilar or CHD 
      involvement)
17 (31.5)
IHD, intrahepatic duct; EHD, extrahepatic duct; CHD, common hepatic 
duct; HCC, hepatocellular carcinoma.
*Each type of obstructive jaundice could have been counted more than once.
Table 3. Endoscopic Interventions of Obstructive Jaundice 
in HCC
Endoscopic interventions Number of patients (%)
ENBD   6 (11.1)
Plastic stent 17 (31.5)
Metal stent 16 (29.6)
EST 12 (22.2)
None 3 (5.6)
Stent length, median 10 cm (range: 5--15 cm)
ENBD, endoscopic nasobiliary drainage; EST, endoscopic sphincterotomy; 
HCC, hepatocellular carcinoma.
Table 4. Variables Predictive or Non-Predictive of Clinical Success and Failure for Endoscopic Intervention
Clinical success (n=23) Clinical failure (n=28) p value
Total bilirubin (mg/dL) 8.1±5.3 23.1±10.4 <0.001
Median days to normalization of total bilirubin or death (days) 47 45 0.744
Liver cirrhosis 19 26 0.390
Child-Pugh classification (A or B/C) 17/6 8/20 0.001
Albumin (g/dL) 3.1±0.4 2.8±0.4 0.013
Patients with alcoholic history   9 20 0.010
Mechanisms of obstructive jaundice (type 1/2/3)* 14/2/7 22/4/2 0.092
Locations of obstruction (type I/II/III/IV/V/VI)† 3/4/1/3/3/9 2/8/2/3/5/8 0.855
Endoscopic interventions (ENBD/PS/MS/EST) 3/11/8/1 3/6/8/8 0.077
Cancer treatment modality (Op./TACE/CTx/RTx/RFA/none) 0/18/12/10/6/1 0/18/14/9/3/3 0.617
ENBD, endoscopic nasobiliary drainage; PS, plastic stent; MS, metal stent; EST, endoscopic sphincterotomy; Op., operation including liver lobectomy and 
segmentectomy; TACE, transhepatic chemoembolization; CTx, chemotherapy; RTx, radiation therapy; RFA, radio frequency ablation (patients could be 
treated with combined modalities); CHD, common hepatic duct; IHD, intrahepatic duct; EHD, extrahepatic duct.
*Type 1, intraluminal obstruction; type 2, hemobilia; type 3, extraluminal compression.
†Type I, IHD involvement without contralateral IHD involvement; type II, IHD involvement with hilar involvement; type III, bilateral IHD involvement with 
hilar involvement; type IV, solitary EHD involvement; type V, multifocal involvement in both IHD and EHD; type VI, solitary hilar or CHD involvement.
Endoscopic Treatment of Obstructive Jaundice in HCC
Yonsei Med J   http://www.eymj.org   Volume 55   Number 5   September 2014 1271
cirrhosis.5 Among various causes of jaundice, obstructive 
jaundice caused by HCC is rare.3 Obstructive jaundice in 
HCC was first reported in 1947 by Mallory, et al.6 In that 
case, the obstructive jaundice was due to invasion by HCC of 
the cystic duct, followed by hemobilia from tumor thrombi. 
As obstructive jaundice can be relieved by active inter-
vention, unlike hepatocellular jaundice, it is clinically im-
portant to be aware that bile duct obstruction can be a cause 
of jaundice in HCC, and distinguishing obstructive jaun-
dice from non-obstructive jaundice should be performed. 
The goals of management in patients with HCC associat-
ed obstructive jaundice are biliary decompression, and, if 
possible, removal of tumor debris.7 This can be done surgi-
cally or endoscopically. The choice of method is based on 
the nature and location of the main tumor mass, severity of 
the symptoms, associated neoplastic strictures, and the pa-
tient’s overall status.8 However, operative treatment is bene-
ficial only in patients with extrahepatic intraluminal biliary 
obstruction.9 Therefore, in patients with advanced diseases, 
endoscopic interventions might be safer and more satisfac-
tory, as a form of palliative treatment.7
Obstructive jaundice can be further specified according 
to the mechanisms and locations of obstruction. First, mech-
anisms of biliary obstruction in HCC were divided into three 
types by Lai and Lau1 These types included tumor invasion 
of a branch of the biliary tree; distal migration to the com-
mon bile duct by necrotic free floating fragments that sepa-
rate from a biliary tumor thrombus; and hemobilia caused 
by bleeding from a tumor that causes the bile duct to fill 
with blood clots that can obstruct bile duct system.10-12 It is 
possible that the mechanisms of obstructive jaundice might 
affect the outcomes of endoscopic intervention. However, 
in our study, the mechanisms of biliary obstruction did not 
affect the results of intervention: we have to point out that 
mg/dL. The area under the ROC curve was 0.904 [95% con-
fidence interval (CI), 0.819--0.989]. Sensitivity and specifici-
ty were 85.7% and 91.3%, respectively. Accordingly, patients 
with a bilirubin level below 12.8 mg/dL before endoscopic 
intervention should show better clinical outcomes. Also, the 
number of patients with better liver function was larger in the 
clinical success group (Child-Pugh grade A or B/C; 17/6 vs. 
8/20, p=0.001). Additionally, alcoholic patients with HCC 
compared to non-alcoholic patients were also higher in the 
clinical failure group (n=20 vs. n=9, p=0.010) (Table 4). We 
also analyzed predictive factors by multivariate analysis. 
The only influencing factor was total bilirubin level at the 
time of endoscopic intervention, regardless of history of al-
cohol consumption [odds ratio 1.223 (95% CI, 1.071--1.396), 
p=0.003]. 
Trends in total bilirubin level for the two groups within 4 
weeks after endoscopic intervention are shown in Fig. 1. 
The median time from diagnosis of HCC to endoscopic in-
tervention was 9.4 months. The median survival after endo-
scopic intervention was significantly longer in the clinical 
success group than in the clinical failure group (5.6 months 
vs. 1.5 months, p≤0.001). The overall median survival time 
from diagnosis of HCC was 19.4 months (95% CI, 7.2--31.6 
months). The median survival days from ERCP among pa-
tients in the clinical failure group was only 1.5 months; most 
of them experienced disease progression and decline in he-
patic function. 
DISCUSSION
Jaundice in HCC usually develops in later stages of the dis-
ease, and can be caused by diffuse cancer infiltration, inva-
sion of the biliary ducts, progressive liver failure, and severe 
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of serum total bilirubin in the clinical failure group before and after ERCP.
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likely to benefit endoscopic interventions. Further prospec-
tive studies with larger population will be needed to objec-
tively compare different methods of intervention. In the fu-
ture, development of guidelines for endoscopic treatment in 
HCC patients with obstructive jaundice will be needed.
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there were multiple mechanisms for obstructive jaundice in 
HCC, and sometimes it is hard to say which mechanism 
was dominant. 
One must also consider which endoscopic interventional 
method should be used. According to our results, stenting 
did not always seem to be the best interventional method in 
HCC. Some HCC patients with obstructive jaundice treated 
with stent insertion showed inadequate relief of jaundice 
according to their underlying hepatic function. Therefore, 
stenting may not be of help for some patients with poor liver 
function. In such cases, stent insertion is not the best treat-
ment for relieving jaundice. Brown and Covey13 suggested 
that stent placement is less effective in jaundice caused by 
intraductal tumor, because tumors can infiltrate into the stent, 
resulting in occlusion. Accordingly, we recommend choos-
ing interventional methods on a case-by-case basis, taking 
into consideration the patient’s clinical condition. 
By considering predictive factors, patients who are more 
likely to benefit from endoscopic intervention may be se-
lected. We found that the factors influencing successful en-
doscopic management include hepatic function at the time 
of the endoscopic procedure and a history of alcohol con-
sumption. Furthermore, median survival after endoscopic 
intervention in the clinical success group was notably lon-
ger than that in the clinical failure group. This implies that 
the factors that predict the success of endoscopic manage-
ment, defined here as a relief of obstruction, also can pre-
dict median survival after the procedure. Many physicians 
are reluctant to treat patients with HCC that have jaundice. 
However, in well selected cases, endoscopic intervention 
not only can resolve obstructive jaundice, but also prolong 
the survival of patients.
We concluded that endoscopic intervention can be an ef-
fective way to relieve obstructive jaundice in patients with 
HCC and can lead to the improvement of quality of life and 
even survival therein. Liver function and a history of alco-
hol consumption should be checked to select patients most 
